ketoconazole has been researched along with Adrenal Insufficiency in 16 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Adrenal Insufficiency: Conditions in which the production of adrenal CORTICOSTEROIDS falls below the requirement of the body. Adrenal insufficiency can be caused by defects in the ADRENAL GLANDS, the PITUITARY GLAND, or the HYPOTHALAMUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levoketoconazole is a ketoconazole stereoisomer in development for treatment of Cushing's syndrome and has not been assessed previously in a clinical trial in patients with Cushing's syndrome." | 9.30 | Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. ( Auchus, RJ; Biller, BMK; Cohen, F; Elenkova, A; Feelders, RA; Fleseriu, M; Geer, EB; Greenman, Y; Pivonello, R; Salvatori, R; Witek, P, 2019) |
| "Orally administered ketoconazole may rarely induce liver injury and adrenal insufficiency." | 8.12 | Arylacetamide deacetylase knockout mice are sensitive to ketoconazole-induced hepatotoxicity and adrenal insufficiency. ( Fukami, T; Hirosawa, K; Honda, S; Kisui, F; Konishi, K; Nagaoka, M; Nakajima, M; Nakano, M; Ogiso, T; Sakai, Y; Tashiro, K; Yamada, T, 2022) |
| "Persistent adrenal insufficiency secondary to ketoconazole therapy has not previously been documented." | 7.67 | Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy. ( Best, TR; Bussell, KL; Jenkins, JK; Murphy, FY; Nicks, SA; Vesely, DL, 1987) |
| "Ketoconazole is a common and effective adjuvant therapy for hypercortisolism, but the major concern is liver enzyme dysfunction." | 5.37 | Pseudotumor cerebri during Cushing's disease treatment with ketoconazole. ( Boschi, V; Costa, TG; Costenaro, F; Czepielewski, MA; Ferreira, NP; Rodrigues, TC; Schuch, T, 2011) |
| "Levoketoconazole is a ketoconazole stereoisomer in development for treatment of Cushing's syndrome and has not been assessed previously in a clinical trial in patients with Cushing's syndrome." | 5.30 | Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. ( Auchus, RJ; Biller, BMK; Cohen, F; Elenkova, A; Feelders, RA; Fleseriu, M; Geer, EB; Greenman, Y; Pivonello, R; Salvatori, R; Witek, P, 2019) |
| "Orally administered ketoconazole may rarely induce liver injury and adrenal insufficiency." | 4.12 | Arylacetamide deacetylase knockout mice are sensitive to ketoconazole-induced hepatotoxicity and adrenal insufficiency. ( Fukami, T; Hirosawa, K; Honda, S; Kisui, F; Konishi, K; Nagaoka, M; Nakajima, M; Nakano, M; Ogiso, T; Sakai, Y; Tashiro, K; Yamada, T, 2022) |
| "Persistent adrenal insufficiency secondary to ketoconazole therapy has not previously been documented." | 3.67 | Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy. ( Best, TR; Bussell, KL; Jenkins, JK; Murphy, FY; Nicks, SA; Vesely, DL, 1987) |
| "Ketoconazole was administered as a single daily oral dose of 200 mg to 12 patients with chronic mucocutaneous candidosis (CMC) of autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED)." | 2.66 | Ketoconazole is effective against the chronic mucocutaneous candidosis of autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED). ( Ahonen, P; Kahanpää, A; Myllärniemi, S; Perheentupa, J, 1986) |
| "Ketoconazole is a common and effective adjuvant therapy for hypercortisolism, but the major concern is liver enzyme dysfunction." | 1.37 | Pseudotumor cerebri during Cushing's disease treatment with ketoconazole. ( Boschi, V; Costa, TG; Costenaro, F; Czepielewski, MA; Ferreira, NP; Rodrigues, TC; Schuch, T, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (37.50) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Nagaoka, M | 1 |
| Fukami, T | 1 |
| Kisui, F | 1 |
| Yamada, T | 1 |
| Sakai, Y | 1 |
| Tashiro, K | 1 |
| Ogiso, T | 1 |
| Konishi, K | 1 |
| Honda, S | 1 |
| Hirosawa, K | 1 |
| Nakano, M | 1 |
| Nakajima, M | 1 |
| Hernandez-Bures, A | 1 |
| White, AG | 1 |
| Riordan, L | 1 |
| Fleseriu, M | 1 |
| Pivonello, R | 1 |
| Elenkova, A | 1 |
| Salvatori, R | 1 |
| Auchus, RJ | 1 |
| Feelders, RA | 1 |
| Geer, EB | 1 |
| Greenman, Y | 1 |
| Witek, P | 1 |
| Cohen, F | 1 |
| Biller, BMK | 1 |
| Sullivant, AM | 1 |
| Lathan, P | 1 |
| Delivanis, DA | 1 |
| Athimulam, S | 1 |
| Bancos, I | 1 |
| Chou, DW | 1 |
| Chung, KM | 1 |
| Lee, CT | 1 |
| Costenaro, F | 1 |
| Rodrigues, TC | 1 |
| Ferreira, NP | 1 |
| Costa, TG | 1 |
| Schuch, T | 1 |
| Boschi, V | 1 |
| Czepielewski, MA | 1 |
| Gallais, V | 1 |
| Lacour, JP | 1 |
| Ortonne, JP | 1 |
| Angeli, A | 1 |
| Masera, RG | 1 |
| Gatti, G | 1 |
| Portilla Sogorb, J | 1 |
| Plana, C | 1 |
| Mauri, M | 1 |
| Picó, A | 1 |
| White, MC | 1 |
| Kendall-Taylor, P | 1 |
| McCance, DR | 1 |
| Ritchie, CM | 1 |
| Sheridan, B | 1 |
| Atkinson, AB | 1 |
| Ahonen, P | 1 |
| Myllärniemi, S | 1 |
| Kahanpää, A | 1 |
| Perheentupa, J | 1 |
| Lamberts, SW | 1 |
| Best, TR | 1 |
| Jenkins, JK | 1 |
| Murphy, FY | 1 |
| Nicks, SA | 1 |
| Bussell, KL | 1 |
| Vesely, DL | 1 |
| Tucker, WS | 1 |
| Snell, BB | 1 |
| Island, DP | 1 |
| Gregg, CR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome[NCT01838551] | Phase 3 | 94 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The response to COR-003 is defined as mean UFC concentration ≤ULN following 6 months of maintenance phase therapy without a prior dose increase during that phase. The proportion of responders at the End of Maintenance Phase visit, following 6 months of treatment in the Maintenance Phase, for all dose groups combined was estimated using a generalized linear model with repeated measurements based on a binomial distribution with a logit link function and with region (US vs. non-US), concurrent CS medical conditions (diabetes [Yes/No], hypertension [Yes/No]), age (rounded median split based on the ITT population), sex, disease duration (years), prior CS medication (Yes/No), prior radiation therapy (Yes/No) as Baseline covariates and visit as an independent factor.~The least squares mean (LSMEAN) estimate of the UFC response after 6 months of treatment in the Maintenance Phase alongside its 95% Wald CI is presented." (NCT01838551)
Timeframe: 6 months of maintenance phase therapy without a prior dose increase during that phase
| Intervention | proportion of subjects meeting endpoint (Least Squares Mean) |
|---|---|
| Levoketoconazole All Doses | .30 |
2 reviews available for ketoconazole and Adrenal Insufficiency
| Article | Year |
|---|---|
[Cutaneous pigmentation disorders in human immunodeficiency virus infection].
Topics: Acquired Immunodeficiency Syndrome; Adrenal Insufficiency; Antiviral Agents; Bleomycin; Clofazimine; | 1992 |
[Mycoses and adrenocortical function. New pathogenetic aspects of adrenal hypofunction].
Topics: Acquired Immunodeficiency Syndrome; Adrenal Cortex Hormones; Adrenal Glands; Adrenal Insufficiency; | 1991 |
2 trials available for ketoconazole and Adrenal Insufficiency
| Article | Year |
|---|---|
Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial.
Topics: Adolescent; Adrenal Insufficiency; Adult; Aged; Alanine Transaminase; Chemical and Drug Induced Live | 2019 |
Ketoconazole is effective against the chronic mucocutaneous candidosis of autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED).
Topics: Adolescent; Adrenal Insufficiency; Adult; Autoimmune Diseases; Candidiasis; Candidiasis, Chronic Muc | 1986 |
12 other studies available for ketoconazole and Adrenal Insufficiency
| Article | Year |
|---|---|
Arylacetamide deacetylase knockout mice are sensitive to ketoconazole-induced hepatotoxicity and adrenal insufficiency.
Topics: Adrenal Insufficiency; Animals; Area Under Curve; Carboxylic Ester Hydrolases; Chemical and Drug Ind | 2022 |
Presumptive iatrogenic hypoadrenocorticism induced by high-dose ketoconazole administration in a dog.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Animals; Antifungal Agents; Dermatomycoses; Dog | 2019 |
Ketoconazole-induced transient hypoadrenocorticism in a dog.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Animals; Dog Diseases; Dogs; Female; Ketoconazol | 2020 |
Modern Management of Mild Autonomous Cortisol Secretion.
Topics: 14-alpha Demethylase Inhibitors; Adrenal Cortex Neoplasms; Adrenal Insufficiency; Adrenalectomy; Adr | 2019 |
Prototheca wickerhamii cutaneous and systemic infections.
Topics: Adrenal Insufficiency; Aged, 80 and over; Cytochrome P-450 CYP3A; Fever; Humans; Infections; Ketocon | 2014 |
Pseudotumor cerebri during Cushing's disease treatment with ketoconazole.
Topics: Adrenal Insufficiency; Child; Diagnosis, Differential; Female; Humans; Ketoconazole; Pituitary ACTH | 2011 |
[Adrenal gland insufficiency induced by ketoconazole in a patient with acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Adrenal Insufficiency; Adult; Humans; Ketoconazole; Male | 1991 |
Adrenal hypofunction in patients taking ketoconazole.
Topics: Adrenal Insufficiency; Humans; Hydrocortisone; Ketoconazole; Male; Prostatic Neoplasms | 1985 |
Acute hypoadrenalism and hepatotoxicity after treatment with ketoconazole.
Topics: Acute Disease; Adrenal Insufficiency; Adult; Chemical and Drug Induced Liver Injury; Cushing Syndrom | 1987 |
[Adrenal cortex insufficiency caused by drugs].
Topics: Adrenal Insufficiency; Etomidate; Humans; Ketoconazole | 1987 |
Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy.
Topics: Adrenal Insufficiency; Blastomycosis; Female; Glucocorticoids; Humans; Ketoconazole; Lung Diseases, | 1987 |
Reversible adrenal insufficiency induced by ketoconazole.
Topics: 17-Hydroxycorticosteroids; Adrenal Insufficiency; Cortodoxone; Cosyntropin; Humans; Hydrocortisone; | 1985 |